vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $151.1M, roughly 1.1× STURM RUGER & CO INC). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 3.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
ESPR vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $151.1M |
| Net Profit | — | — |
| Gross Margin | — | 17.8% |
| Operating Margin | 50.6% | 2.3% |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 3.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $151.1M | ||
| Q3 25 | $87.3M | $126.8M | ||
| Q2 25 | $82.4M | $132.5M | ||
| Q1 25 | $65.0M | $135.7M | ||
| Q4 24 | $69.1M | $145.8M | ||
| Q3 24 | $51.6M | $122.3M | ||
| Q2 24 | $73.8M | $130.8M | ||
| Q1 24 | $137.7M | $136.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $1.6M | ||
| Q2 25 | $-12.7M | $-17.2M | ||
| Q1 25 | $-40.5M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $4.7M | ||
| Q2 24 | $-61.9M | $8.3M | ||
| Q1 24 | $61.0M | $7.1M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | 50.6% | 2.3% | ||
| Q3 25 | -11.4% | -2.7% | ||
| Q2 25 | 8.6% | -15.6% | ||
| Q1 25 | -34.0% | 6.2% | ||
| Q4 24 | -6.4% | 7.8% | ||
| Q3 24 | -31.0% | 3.1% | ||
| Q2 24 | 3.5% | 6.9% | ||
| Q1 24 | 52.5% | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 1.2% | ||
| Q2 25 | -15.4% | -13.0% | ||
| Q1 25 | -62.2% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 3.9% | ||
| Q2 24 | -83.9% | 6.3% | ||
| Q1 24 | 44.3% | 5.2% |
| Q4 25 | $0.32 | $0.22 | ||
| Q3 25 | $-0.16 | $0.10 | ||
| Q2 25 | $-0.06 | $-1.05 | ||
| Q1 25 | $-0.21 | $0.46 | ||
| Q4 24 | $-0.14 | $0.62 | ||
| Q3 24 | $-0.15 | $0.28 | ||
| Q2 24 | $-0.33 | $0.47 | ||
| Q1 24 | $0.34 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $283.8M |
| Total Assets | $465.9M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $92.5M | ||
| Q3 25 | $92.4M | $80.8M | ||
| Q2 25 | $86.1M | $101.4M | ||
| Q1 25 | $114.6M | $108.3M | ||
| Q4 24 | $144.8M | $105.5M | ||
| Q3 24 | $144.7M | $96.0M | ||
| Q2 24 | $189.3M | $105.6M | ||
| Q1 24 | $226.6M | $115.3M |
| Q4 25 | $-302.0M | $283.8M | ||
| Q3 25 | $-451.4M | $279.6M | ||
| Q2 25 | $-433.5M | $289.3M | ||
| Q1 25 | $-426.2M | $321.5M | ||
| Q4 24 | $-388.7M | $319.6M | ||
| Q3 24 | $-370.2M | $314.9M | ||
| Q2 24 | $-344.2M | $321.5M | ||
| Q1 24 | $-294.3M | $332.0M |
| Q4 25 | $465.9M | $342.0M | ||
| Q3 25 | $364.0M | $342.3M | ||
| Q2 25 | $347.1M | $349.5M | ||
| Q1 25 | $324.0M | $379.0M | ||
| Q4 24 | $343.8M | $384.0M | ||
| Q3 24 | $314.1M | $373.5M | ||
| Q2 24 | $352.3M | $376.7M | ||
| Q1 24 | $373.1M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $15.5M |
| Free Cash FlowOCF − Capex | — | $12.3M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $15.5M | ||
| Q3 25 | $-4.3M | $12.9M | ||
| Q2 25 | $-31.4M | $14.7M | ||
| Q1 25 | $-22.6M | $11.1M | ||
| Q4 24 | $-35.0M | $20.0M | ||
| Q3 24 | $-35.3M | $9.4M | ||
| Q2 24 | $-7.2M | $18.7M | ||
| Q1 24 | $53.8M | $7.3M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | $-35.5M | $2.6M | ||
| Q2 24 | $-7.3M | $10.1M | ||
| Q1 24 | $53.8M | $5.6M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | -68.7% | 2.1% | ||
| Q2 24 | -9.9% | 7.7% | ||
| Q1 24 | 39.0% | 4.1% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.3% | 5.5% | ||
| Q2 24 | 0.1% | 6.6% | ||
| Q1 24 | 0.1% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | 0.88× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
